Nehlmeier, Inga http://orcid.org/0000-0002-8752-7491
Kempf, Amy
Arora, Prerna
Cossmann, Anne
Dopfer-Jablonka, Alexandra http://orcid.org/0000-0001-7129-100X
Stankov, Metodi V.
Schulz, Sebastian R. http://orcid.org/0000-0001-6554-3346
Jäck, Hans-Martin http://orcid.org/0000-0002-6332-8463
Behrens, Georg M. N. http://orcid.org/0000-0003-3111-621X
Pöhlmann, Stefan http://orcid.org/0000-0001-6086-9136
Hoffmann, Markus http://orcid.org/0000-0003-4603-7696
Funding for this research was provided by:
European Commission (Defeat Corona, ZW7-8515131, Defeat Corona, ZW7-8515131, 101057100)
Deutsches Zentrum für Infektionsforschung (80018019238)
Niedersächsische Ministerium für Wissenschaft und Kultur (14-76103-184, COFONI 7FF22, COFONI 6FF22)
Deutsche Forschungsgemeinschaft (PO 716/11-1)
Article History
Received: 18 April 2023
Accepted: 25 April 2023
First Online: 8 May 2023
Competing interests
: SP and MH conducted contract research (testing of vaccine sera for neutralising activity against SARS-CoV-2) for Valneva unrelated to this work. GMNB served as advisor for Moderna and SP served as advisor for BioNTech, unrelated to this work. All other authors declare no competing interests.